Medical Xpress covers an implant approach to type 2 diabetes that uses a small catalyst to bring glucose down. Not a peptide or GLP-1 story.
Recap by typeshit. Full story at Medical Xpress.
Avi Roy points out that the largest test so far found no memory benefit from the drug in Ozempic, despite hopes raised by health record studies.
Balwinder Singh and Raman Baweja link GLP-1 use to less kidney replacement therapy in bipolar patients with CKD, and flag lithium toxicity cases.
Yale Medicine says 5% to 10% of people on GLP-1 weight loss drugs see little result, and points to diet as one factor that can blunt the effect.
24:26
A doctor's explainer sorting peptides into eight broad categories. An evergreen overview for anyone still learning the basics.
8:32
Archibald follows up his earlier retatrutide video with a look at its uses. Retatrutide is still an investigational drug and is not FDA approved.
A shared research summary evaluating how GLP-1 receptor agonists affect deaths and hospital stays in people with type 2 diabetes. Details are thin here.
Loading…